In 404 adults with type 2 diabetes, oral once-daily elecoglipron (5–75 mg) lowered HbA1c by 0·91% to 1·88% at 26 weeks versus 0·15% with placebo. Adverse events, mainly gastrointestinal, occurred in 63–87% on elecoglipron vs 63% on placebo.
RCTn = 406
Aroda et al. Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with type 2 diabetes (SOLSTICE): a multicentre, phase 2b, randomised, placebo-controlled trial